Translating experimental diabetic nephropathy studies from mice to men

Contributions to Nephrology

Volumn 170, Issue , 2011, Pages 156-164

  Breyer, Matthew D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMINURIA; ANIMAL; ARTICLE; DIABETIC NEPHROPATHY; DISEASE MODEL; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY; MOUSE; PATHOLOGY;

ALBUMINURIA; ANIMALS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MICE;

EID: 84925956136     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000325651     Document Type: Article

References (56)

1. Foley RN, Collins AJ: The growing economic burden of diabetic kidney disease. Curr Diab Rep 2009;9:460-465.
2. Gilbertson DT, Liu J, Xue JL, Louis TA, Solid CA, Ebben JP, Collins AJ: Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 2005;16:3736-3741. (Pubitemid 46211296)
3. Yang H, Bell TA, Churchill GA, Pardo-Manuel de Villena F: On the subspecific origin of the laboratory mouse. Nat Genet 2007; 39:1100-1107. (Pubitemid 47340646)
4. Kohan DE: Progress in gene targeting: Using mutant mice to study renal function and disease. Kidney Int 2008;74:427-437.
5. Beck JA, Lloyd S, Hafezparast M, Lennon-Pierce M, Eppig JT, Festing MF, Fisher EM: Genealogies of mouse inbred strains. Nat Genet 2000;24:23-25. (Pubitemid 30041415)
6. Adler AI, Stevens RJ, Manley SE, BilousRW, Cull CA, Holman RR: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-232. (Pubitemid 35463925)
7. Finne P, Reunanen A, Stenman S, Groop PH, Gronhagen-Riska C: Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005;294:1782-1787. (Pubitemid 41434624)
8. Iyengar SK, Abboud, HE, Goddard KA, et al: Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: The family investigation of nephropathy and diabetes. Diabetes: 2007;56:1577-1585. (Pubitemid 46842614)
9. Rogus JJ, Poznik GD, Pezzolesi MG, et al: High-density single nucleotide polymorphism genome-wide linkage scan for susceptibility genes for diabetic nephropathy in type 1 diabetes: Discordant sibpair approach. Diabetes 2008;57:2519-2526.
10. Breyer MD, Bottinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, Sharma K: Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005;16:27-45. (Pubitemid 43073154)
11. Brosius FC 3rd, Alpers CE, Bottinger EP, et al: Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009;20:2503-2512.
12. Gurley SB, Clare SE, Snow KP, Hu A, Meyer TW, Coffman TM: Impact of genetic background on nephropathy in diabetic mice. Am J Physiol Renal Physiol 2006;290:F214-F222.
13. Qi Z, Fujita H, Jin J, Davis LS, Wang Y, Fogo AB, Breyer MD: Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 2005;54:2628-2637. (Pubitemid 41233584)
14. Kimmelstiel P, Wilson C: Intercapillary lesions in the glomeruli of kidney. Am J Pathol 1936;12:83-97.
15. Newburger, RA, Peters PJ: Intercapillary glomerulosclerosis: A syndrome of diabetes, hypertension, and albuminuria. Arch Int Med 1939;64:1252-1264.
16. Wilson JL, Root HF, Marble A: Diabetic nephropathy; a clinical syndrome. N Engl J Med 1951;245:513-517.
17. Gurley SB, Mach CL, Stegbauer J, Yang J, Snow KP, Hu A, Meyer TW, Coffman TM: Influence of genetic background on albuminuria and kidney injury in Ins2(+/C96Y) (Akita) mice. Am J Physiol Renal Physiol 2010;298:F788-F795.
18. Hudkins KL, Pichaiwong W, Wietecha T, et al: BTBR Ob/Ob mutant mice model progressive diabetic nephropathy. J Am Soc Nephrol 2010;21:1533-1542.
19. Bohle A, Wehrmann M, Bogenschutz O, Batz C, Muller CA, Muller GA: The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 1991; 187:251-259.
20. Lane P, Steffes MW, Mauer SM: Structuralfunctional relationships in type I insulindependent diabetes mellitus in humans. J Diabet Complications 1991;5:69-71.
21. White KE, Bilous RW: Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease. J Am Soc Nephrol 2000;11:1667-1673.
22. Mauer M, Zinman B, Gardiner R, et al: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361: 40-51.
23. Zhao HJ, Wang S, Cheng H, Zhang MZ, Takahashi T, Fogo AB, Breyer MD, Harris RC: Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006;17: 2664-2669. (Pubitemid 44484656)
24. Zheng S, Noonan WT, Metreveli NS, Coventry S, Kralik PM, Carlson EC, Epstein PN: Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes 2004;53:3248-3257. (Pubitemid 39564502)
25. Ninomiya, T, Perkovic V, de Galan BE, et al: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20:1813-1821.
26. Eijkelkamp WB, Zhang Z, Remuzzi G, et al: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007;18:1540-1546. (Pubitemid 46717521)
27. Mann JF, Green D, Jamerson K, Ruilope, LM, Kuranoff SJ, Littke T, Viberti G: Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21:527-535.
28. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110:921-927. (Pubitemid 39128617)
29. Szoka PR, Paigen K: Regulation of mouse major urinary protein production by the Mup-A gene. Genetics 1978;90:597-612. (Pubitemid 9087533)
30. Hansen HP, Hovind P, Jensen BR, Parving HH: Diurnal variations of glomerular filtration rate and albuminuria in diabetic nephropathy. Kidney Int 2002;61:163-168. (Pubitemid 34075143)
31. Levey, AS, Cattran, D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske B, Hostetter T: Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009;54:205-226.
32. Senador D, Kanakamedala K, Irigoyen MC, Morris M, Elased KM: Cardiovascular and autonomic phenotype of db/db diabetic mice. Exp Physiol 2009;94:648-658.
33. Sharma K, McCueP, Dunn SR: Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 2003;284:F1138-F1144. (Pubitemid 36578440)
34. Bagi Z, Erdei N, Toth A, Li W, Hintze TH, Koller A, Kaley G: Type 2 diabetic mice have increased arteriolar tone and blood pressure: Enhanced release of COX-2-derived constrictor prostaglandins. Arterioscler Thromb Vasc Biol 2005;25:1610-1616. (Pubitemid 41098929)
35. Mohan S, Reddick RL, Musi N, Horn DA, Yan B, Prihoda TJ, Natarajan M, Abboud-Werner SL: Diabetic eNOS knockout mice develop distinct macro-and microvascular complications. Lab Invest 2008;88:515-528. (Pubitemid 351581457)
36. Riches AC, Sharp JG, Thomas DB, Smith SV: Blood volume determination in the mouse. J Physiol 1973;228:279-284.
37. Sluiter W, Oomens LW, Brand A, Van Furth R: Determination of blood volume in the mouse with 51 chromium-labelled erythrocytes. J Immunol Methods 1984;73:221-225. (Pubitemid 14019676)
38. Takahashi N, Boysen G, Li F, Li Y, Swenberg JA: Tandem mass spectrometry measurements of creatinine in mouse plasma and urine for determining glomerular filtration rate. Kidney Int 2007;71:266-271. (Pubitemid 46160928)
39. Dunn SR, Qi Z, Bottinger EP, Breyer MD, Sharma K: Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int 2004;65:1959-1967. (Pubitemid 38591050)
40. Palm M, Lundblad A: Creatinine concentration in plasma from dog, rat, and mouse: A comparison of 3 different methods. Vet Clin Pathol 2005;34:232-236. (Pubitemid 41412485)
41. Yuen PS, Dunn SR, Miyaji T, Yasuda H, Sharma K, Star RA: A simplified method for HPLC determination of creatinine in mouse serum. Am J Physiol Renal Physiol 2004;286:F1116-F1119. (Pubitemid 38656367)
42. Keppler A, Gretz N, Schmidt R, Kloetzer HM, Groene HJ, Lelongt B, Meyer M, Sadick M, Pill J: Plasma creatinine determination in mice and rats: An enzymatic method compares favorably with a high-performance liquid chromatography assay. Kidney Int 2007; 71:74-78. (Pubitemid 44967737)
43. Evans GO: The use of an enzymatic kit to measure plasma creatinine in the mouse and three other species. Comp Biochem Physiol B 1986;85:193-195.
44. Eisner C, Faulhaber-Walter R, Wang Y, Leelahavanichkul A, Yuen PS, Mizel D, Star RA, Briggs, JP, Levine M, Schnermann J: Major contribution of tubular secretion to creatinine clearance in mice. Kidney Int 2010;77:519-526.
45. Lorenz JN, Gruenstein E: A simple, nonradioactive method for evaluating singlenephron filtration rate using FITC-inulin. Am J Physiol 1999;276:F172-F177. (Pubitemid 29061738)
46. Qi Z, Whitt I, Mehta A, Jin J, Zhao M, Harris RC, Fogo AB, Breyer MD: Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 2004;286:F590-F596. (Pubitemid 38233654)
47. Leiter EH: Multiple low-dose streptozotocininduced hyperglycemia and insulitis in C57BL mice: Influence of inbred background, sex, and thymus. Proc Natl Acad Sci USA 1982;79:630-634. (Pubitemid 12137765)
48. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, Yuzawa Y, Atkinson MA, Johnson RJ, Croker B: Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007;18: 539-550. (Pubitemid 46193319)
49. Shimasaki Y, Yasue H, Yoshimura M, et al: Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol 1998;31:1506-1510. (Pubitemid 28273291)
50. Zanchi A, Moczulski DK, Hanna, LS, Wantman M, Warram JH, Krolewski AS: Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 2000;57:405-413. (Pubitemid 30430632)
51. Shin Shin, Y, Baek SH, Chang KY, Park CW, Yang CW, Jin DC, Kim YS, Chang YS, Bang BK: Relations between eNOS Glu298Asp polymorphism and progression of diabetic nephropathy. Diabetes Res Clin Pract 2004; 65:257-265. (Pubitemid 39141182)
52. Sato W, Kosugi T, Zhang L, et al: The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy. Lab Invest 2008;88:949-961.
53. Lewis A, Steadman R, Manley P, Craig K, de la Motte C, Hascall V, Phillips AO: Diabetic nephropathy, inflammation, hyaluronan and interstitial fibrosis. Histol Histopathol 2008;23:731-739. (Pubitemid 351552358)
54. Okazaki M, Saito Y, Udaka Y, Maruyama M, Murakami H, Ota S, Kikuchi T, Oguchi K: Diabetic nephropathy in KK and KK-Ay mice. Exp Anim 2002;51:191-196.
55. Ito T, Tanimoto M, Yamada K, et al: Glomerular changes in the KK-Ay/Ta mouse: A possible model for human type 2 diabetic nephropathy. Nephrology (Carlton) 2006; 11:29-35.
56. Ninomiya H, Inomata T, Ogihara K: Microvasculature of hydronephrotic kidneys in KK-A(Y) mice. J Vet Med Sci 2000; 62:1093-1098.